Scarica l'app Stockscreener
3.705
4.07%
0.145
Dopo l'orario di chiusura:
3.67
-0.035
-0.94%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZNTL Giù?
Forum
Previsione
Zentalis Pharmaceuticals Inc Borsa (ZNTL) Ultime notizie
Zentalis Pharmaceuticals closes $92.6 million stock offering - Investing.com
Zentalis Pharmaceuticals closes $92.6 million stock offering By Investing.com - Investing.com India
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Zentalis raises $92.6M for trials, filings and what follows - Stock Titan
GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharmaceuticals Shares Fall After Pricing $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering - Latham & Watkins LLP
symbol__ Stock Quote Price and Forecast - CNN
Why is Zentalis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com Canada
Why is Zentalis Pharmaceuticals stock tumbling today? - Investing.com
Zentalis Pharmaceuticals Shares Fall on Public Offering Pricing - Moomoo
Zentalis Pharmaceuticals (ZNTL) Prices $80.5M Public Offering to Fund Clinical Trials - GuruFocus
Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 By Investing.com - Investing.com Australia
Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 - Investing.com
Zentalis Pharmaceuticals Prices $80.5 Million Public Offering of Common Stock - Quiver Quantitative
Zentalis Sets $3.50 Share Price to Fund Clinical Trials - Stock Titan
Zentalis Pharmaceuticals Announces Pricing Of Underwritten Public Offering - TradingView
Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis - Stock Titan
Zentalis Pharmaceuticals announces public stock offering - Investing.com
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering - TradingView
Zentalis Pharmaceuticals stock falls on public offering news By Investing.com - Investing.com Nigeria
Zentalis Pharmaceuticals announces public stock offering By Investing.com - Investing.com South Africa
Zentalis Pharmaceuticals stock falls on public offering news - Investing.com
Mizuho Securities Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
HC Wainwright Analysts Decrease Earnings Estimates for ZNTL - MarketBeat
Zentalis Pharmaceuticals (ZNTL) Slips to $4.15 Amid Cautious Biotech TradingDemand Zone - dars.gov.et
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Cut to Strong Sell at Wall Street Zen - MarketBeat
Morgan Stanley Maintains Zentalis Pharmaceuticals(ZNTL.US) With Hold Rating, Raises Target Price to $5 - Moomoo
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Zentalis Highlights Q2 Results and Azenosertib Progress - The Globe and Mail
Wedbush Adjusts Price Target on Zentalis Pharmaceuticals to $5 From $4, Maintains Neutral Rating - Moomoo
Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $7.44, Implies 49% Upside - TradingView
Morgan Stanley Adjusts PT on Zentalis Pharmaceuticals to $5 From $4, Maintains Equalweight Rating - marketscreener.com
Renaissance Technologies LLC Lowers Position in Zentalis Pharmaceuticals, Inc. $ZNTL - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results - MarketBeat
ZNTL Advances Clinical Trials for Ovarian Cancer Drug Amid Valua - GuruFocus
Zentalis Pharmaceuticals, Inc. 2Q 2026: Net loss $(42.3M), EPS $(0.59) — 10-Q Summary - TradingView
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Zentalis Q2 FY26 net loss widens to $42.29 million - Bitget
ZNTL: Clinical and regulatory progress advances, with $174.6M cash runway into late 2027 despite higher losses - TradingView
BlackRock, Inc. Expands Stake in Zentalis Pharmaceuticals (ZNTL) with Strategic Share Addition - GuruFocus
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BlackRock (NYSE: BLK) discloses 5.2% ownership in Zentalis Pharmaceuticals (ZNTL) - Stock Titan
Zentalis Pharmaceuticals Market Sentiment - Benzinga España
Zentalis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ZNTL - TradingView
TradingKey - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Institutional Confidence - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ZNTL|Zentalis Pharmaceuticals Inc|Price:4.445|Chg%:-0.055 - TradingKey
ZNTL Initiated Coverage by Rodman & Renshaw -- Price Target Anno - GuruFocus
Rodman & Renshaw initiates Zentalis stock with buy on drug potential - Investing.com Canada
Rodman & Renshaw Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) - MarketBeat
ManpowerGroup posts upbeat Q2 earnings, joins Docebo, Zentalis Pharmaceuticals and other big stocks moving higher on Friday - MSN
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? - Yahoo! Finance Canada
ZENTALIS PHARMACEUTICALS INC : MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $8 - Bitget
Weekly Recap: DENALI Part 1b azenosertib OS data and Mizuho Outperform $8 - TradingView
ZNTL Jumps As Mizuho Targets Upside On Cancer Drug - StocksToTrade
Zentalis Pharmaceuticals Surges 11.8%: Key Levels and Potential CatalystsCounter Trend Trade - dars.gov.et
Mizuho Securities Initiates a Buy Rating on Zentalis Pharmaceuticals (ZNTL) - The Globe and Mail
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 - The Manila Times
Zentalis Pharmaceuticals Initiated at Outperform by Mizuho - Moomoo
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):